The discussion is slated for 9:30 AM ET and will be broadcast live via the investor relations portal on the company's website. Following the conclusion of the session, an archived replay will remain accessible for those unable to attend the real-time event.
In section Releases
Compugen Management to Address AI Drug Discovery at H.C. Wainwright
Compugen leadership is scheduled to join the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference on October 8, 2026. The virtual fireside chat will highlight the Israeli firm’s reliance on its proprietary computational platform to identify novel targets within the competitive landscape of cancer immunotherapy.
Compugen currently leans on its Unigen discovery engine to drive an immuno-oncology pipeline that includes notable clinical-stage assets like COM701, rilvegostomig, and GS-0321. The company’s lead candidate, COM701, is currently undergoing evaluation in the MAIA-ovarian trial, while its bispecific antibody rilvegostomig continues to move through various clinical phases under an exclusive licensing agreement with AstraZeneca. Additionally, the high-affinity antibody GS-0321 is being assessed in a Phase 1 study in collaboration with Gilead.
Comments (0)
No comments yet. Be the first!